share_log

西藏药业(600211.SH):国内市场已完成依姆多上市许可持有人变更

Tibet Pharmaceutical (600211.SH): The domestic market has completed the change of Imdo listing license holder

Gelonghui Finance ·  Oct 10, 2023 10:18

Gelonghui October 10?In a survey conducted by a specific subject, 600211.SH said that Imdo's sales are divided into domestic and overseas markets. The domestic market has completed the change of Imdor listing license holder, and has commissioned qualified production plants to produce Imdor products; at the same time, the company is promoting the relevant work of new API suppliers and drug manufacturers, and the application materials have been submitted to the Drug Evaluation Center of the State Drug Administration and accepted. Overseas, due to the inconsistencies in conversion progress and drug administration systems involving more than 40 countries and regions, some regions and countries are in the process of transformation.

The Imdo intangible assets group has an amortization life of 20 years and an impairment test is conducted every year on the balance sheet date to determine whether the asset shows signs of impairment.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment